Share Price and Basic Stock Data
Last Updated: January 16, 2026, 12:15 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vadivarhe Speciality Chemicals Ltd operates in the specialty chemicals sector, focusing on niche products. The company’s revenue trajectory has shown volatility over the years. In FY 2023, sales reported ₹43.68 Cr, which marked a significant increase from ₹21.45 Cr in FY 2022. However, the revenue for FY 2024 declined to ₹40.08 Cr, reflecting fluctuations in demand or operational challenges. Quarterly sales data indicates a recent uptick with ₹25.98 Cr reported for March 2024, suggesting a recovery trend. Nevertheless, the sales for September 2024 dipped to ₹14.47 Cr, raising concerns about sustainability. The company has experienced a substantial increase in sales in the first half of FY 2025, with projections indicating a continuation of this trend, reaching ₹23.44 Cr by March 2025. This inconsistency in revenue generation highlights both potential growth opportunities and the inherent risks associated with market dynamics in the specialty chemicals sector.
Profitability and Efficiency Metrics
Vadivarhe’s profitability metrics illustrate significant challenges, as the company reported a net profit of ₹1.15 Cr in FY 2023, contrasting sharply with the net loss of ₹9.61 Cr in FY 2022. However, this positive shift was short-lived, as FY 2024 net profit stood at just ₹0.06 Cr, indicating ongoing struggles. The operating profit margin (OPM) has fluctuated, marked by a notable recovery to 7.92% in FY 2023, compared to the negative margins recorded in previous years, yet it declined to 11.48% in FY 2024. The interest coverage ratio (ICR) reflects a precarious situation, standing at -4.63x for FY 2025, indicating that the company may face difficulties in meeting its interest obligations. Additionally, the cash conversion cycle (CCC) of 108.78 days raises concerns regarding operational efficiency, suggesting that the company may take longer to convert its investments in inventory and receivables back into cash.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vadivarhe Speciality Chemicals Ltd shows a concerning picture, particularly regarding reserves and borrowings. The company reported reserves of -₹19.41 Cr in FY 2025, a stark decline from previous years, indicating a potential solvency issue. Total borrowings increased to ₹31.37 Cr in September 2025, which raises the debt-to-equity ratio significantly, suggesting a reliance on external financing. The price-to-book value ratio (P/BV) stood at -12.09x, indicating that the market perceives the company’s net assets as having negative value. Furthermore, the return on capital employed (ROCE) has been inconsistent, reported at -22.66% for FY 2025, reflecting poor capital efficiency. The current ratio of 0.89x suggests liquidity concerns, as it falls below the typical benchmark of 1.0x, indicating potential difficulty in meeting short-term obligations. These financial ratios point towards vulnerabilities in Vadivarhe’s financial health, necessitating immediate attention to improve performance.
Shareholding Pattern and Investor Confidence
Vadivarhe’s shareholding structure reveals a strong promoter presence, which stood at 66.83% as of March 2025. This high level of promoter ownership typically instills confidence among investors, suggesting commitment to the company’s long-term vision. However, the public shareholding has increased to 33.17%, indicating a gradual shift towards broader market participation. Despite this, the number of shareholders has fluctuated, with 448 shareholders reported as of September 2025, reflecting investor interest but also potential volatility in shareholding patterns. The stability of promoter holdings, which have slightly decreased from 74.64% in December 2022, may raise concerns about insider confidence in the company’s future. The lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests limited institutional backing, which could hinder the company’s ability to attract significant capital for growth initiatives. Overall, while promoter confidence remains a strength, the lack of institutional investment could be a risk factor for wider market acceptance.
Outlook, Risks, and Final Insight
Looking ahead, Vadivarhe Speciality Chemicals Ltd faces a complex landscape characterized by both opportunities and risks. The company’s recent sales growth provides a glimmer of hope for recovery, but the volatility in profitability raises red flags about operational sustainability. The high debt levels and negative reserves present significant risks, potentially impacting the company’s ability to finance growth and manage cash flow effectively. Strengths include the high promoter stake, which could drive strategic decision-making, and recent improvements in sales figures. However, the challenges related to profitability, liquidity, and operational efficiency cannot be overlooked. Should the company successfully address these financial vulnerabilities and stabilize its operational performance, it could pave the way for a more robust recovery. Conversely, failure to do so may result in further deterioration of its financial standing, necessitating a cautious approach from current and prospective investors.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 343 Cr. | 37.5 | 74.0/36.8 | 21.3 | 20.5 | 1.07 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 28.5 Cr. | 58.0 | 88.8/55.0 | 13.6 | 89.6 | 1.73 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 46.8 Cr. | 688 | 899/600 | 21.6 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,361 Cr. | 74.1 | 111/68.2 | 22.2 | 22.0 | 0.67 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 546 Cr. | 220 | 393/214 | 19.6 | 93.8 | 1.14 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,046.60 Cr | 648.98 | 58.54 | 182.97 | 0.47% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.02 | 13.85 | 12.62 | 9.82 | 11.63 | 21.36 | 22.32 | 14.10 | 25.98 | 14.47 | 23.44 | 17.04 |
| Expenses | 16.73 | 14.32 | 12.78 | 12.39 | 15.98 | 19.80 | 20.58 | 15.01 | 21.04 | 16.41 | 27.92 | 19.50 |
| Operating Profit | -4.71 | -0.47 | -0.16 | -2.57 | -4.35 | 1.56 | 1.74 | -0.91 | 4.94 | -1.94 | -4.48 | -2.46 |
| OPM % | -39.18% | -3.39% | -1.27% | -26.17% | -37.40% | 7.30% | 7.80% | -6.45% | 19.01% | -13.41% | -19.11% | -14.44% |
| Other Income | 0.27 | 0.90 | 0.18 | 0.33 | 0.34 | 0.28 | 0.82 | 0.19 | 0.30 | 0.11 | 0.22 | 0.28 |
| Interest | 0.67 | 0.59 | 0.64 | 0.87 | 0.70 | 0.78 | 0.69 | 0.71 | 0.57 | 0.58 | 0.75 | 0.73 |
| Depreciation | 0.82 | 0.90 | 0.91 | 0.91 | 0.88 | 0.89 | 0.89 | 0.87 | 0.86 | 0.89 | 0.95 | 0.95 |
| Profit before tax | -5.93 | -1.06 | -1.53 | -4.02 | -5.59 | 0.17 | 0.98 | -2.30 | 3.81 | -3.30 | -5.96 | -3.86 |
| Tax % | -32.38% | 0.00% | 11.11% | 0.00% | 0.00% | 0.00% | 0.00% | 63.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -4.01 | -1.06 | -1.70 | -4.01 | -5.59 | 0.17 | 0.98 | -3.75 | 3.81 | -3.30 | -5.96 | -3.85 |
| EPS in Rs | -3.14 | -0.83 | -1.33 | -3.14 | -4.37 | 0.13 | 0.77 | -2.93 | 2.98 | -2.58 | -4.66 | -3.01 |
Last Updated: December 28, 2025, 3:32 pm
Below is a detailed analysis of the quarterly data for Vadivarhe Speciality Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 17.04 Cr.. The value appears to be declining and may need further review. It has decreased from 23.44 Cr. (Mar 2025) to 17.04 Cr., marking a decrease of 6.40 Cr..
- For Expenses, as of Sep 2025, the value is 19.50 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 27.92 Cr. (Mar 2025) to 19.50 Cr., marking a decrease of 8.42 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.46 Cr.. The value appears strong and on an upward trend. It has increased from -4.48 Cr. (Mar 2025) to -2.46 Cr., marking an increase of 2.02 Cr..
- For OPM %, as of Sep 2025, the value is -14.44%. The value appears strong and on an upward trend. It has increased from -19.11% (Mar 2025) to -14.44%, marking an increase of 4.67%.
- For Other Income, as of Sep 2025, the value is 0.28 Cr.. The value appears strong and on an upward trend. It has increased from 0.22 Cr. (Mar 2025) to 0.28 Cr., marking an increase of 0.06 Cr..
- For Interest, as of Sep 2025, the value is 0.73 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.75 Cr. (Mar 2025) to 0.73 Cr., marking a decrease of 0.02 Cr..
- For Depreciation, as of Sep 2025, the value is 0.95 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.95 Cr..
- For Profit before tax, as of Sep 2025, the value is -3.86 Cr.. The value appears strong and on an upward trend. It has increased from -5.96 Cr. (Mar 2025) to -3.86 Cr., marking an increase of 2.10 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -3.85 Cr.. The value appears strong and on an upward trend. It has increased from -5.96 Cr. (Mar 2025) to -3.85 Cr., marking an increase of 2.11 Cr..
- For EPS in Rs, as of Sep 2025, the value is -3.01. The value appears strong and on an upward trend. It has increased from -4.66 (Mar 2025) to -3.01, marking an increase of 1.65.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.87 | 19.03 | 26.28 | 35.03 | 25.56 | 32.36 | 28.58 | 26.47 | 21.45 | 43.68 | 40.08 | 37.91 | 40.48 |
| Expenses | 11.18 | 11.52 | 18.89 | 24.64 | 21.80 | 29.97 | 37.82 | 27.01 | 28.24 | 40.22 | 35.48 | 43.80 | 47.42 |
| Operating Profit | 2.69 | 7.51 | 7.39 | 10.39 | 3.76 | 2.39 | -9.24 | -0.54 | -6.79 | 3.46 | 4.60 | -5.89 | -6.94 |
| OPM % | 19.39% | 39.46% | 28.12% | 29.66% | 14.71% | 7.39% | -32.33% | -2.04% | -31.66% | 7.92% | 11.48% | -15.54% | -17.14% |
| Other Income | 0.11 | 0.11 | 0.14 | 1.05 | 0.45 | 0.40 | 0.37 | 1.08 | 0.66 | 1.09 | 0.47 | 0.19 | 0.50 |
| Interest | 1.02 | 0.89 | 1.21 | 0.85 | 0.77 | 1.11 | 1.37 | 1.32 | 1.69 | 1.61 | 1.83 | 1.72 | 1.48 |
| Depreciation | 1.65 | 1.09 | 1.36 | 1.14 | 1.27 | 1.63 | 1.75 | 1.81 | 1.79 | 1.79 | 1.74 | 1.85 | 1.90 |
| Profit before tax | 0.13 | 5.64 | 4.96 | 9.45 | 2.17 | 0.05 | -11.99 | -2.59 | -9.61 | 1.15 | 1.50 | -9.27 | -9.82 |
| Tax % | 46.15% | 29.61% | 13.51% | 36.51% | 18.43% | -20.00% | -17.93% | 6.56% | 0.00% | 0.00% | 96.67% | 0.00% | |
| Net Profit | 0.07 | 3.98 | 4.29 | 6.01 | 1.77 | 0.06 | -9.84 | -2.76 | -9.61 | 1.15 | 0.06 | -9.27 | -9.81 |
| EPS in Rs | 1.45 | 82.27 | 88.67 | 4.97 | 1.38 | 0.05 | -7.70 | -2.16 | -7.52 | 0.90 | 0.05 | -7.25 | -7.67 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 5585.71% | 7.79% | 40.09% | -70.55% | -96.61% | -16500.00% | 71.95% | -248.19% | 111.97% | -94.78% | -15550.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -5577.93% | 32.30% | -110.64% | -26.06% | -16403.39% | 16571.95% | -320.14% | 360.16% | -206.75% | -15455.22% |
Vadivarhe Speciality Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 21% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 2% |
| TTM: | -11763% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 34% |
| 3 Years: | 5% |
| 1 Year: | -54% |
| Return on Equity | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -54% |
| 3 Years: | -60% |
| Last Year: | -503% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 4, 2025, 2:11 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.84 | 4.84 | 4.84 | 12.09 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 | 12.78 |
| Reserves | 5.73 | 9.68 | 12.62 | 11.38 | 14.64 | 14.70 | 4.87 | 2.11 | -7.50 | -6.36 | -6.29 | -15.56 | -19.41 |
| Borrowings | 14.35 | 11.24 | 10.65 | 12.74 | 9.66 | 20.98 | 19.67 | 23.45 | 24.42 | 26.94 | 26.18 | 36.03 | 31.37 |
| Other Liabilities | 7.75 | 3.67 | 5.09 | 9.52 | 7.13 | 9.28 | 14.00 | 8.84 | 11.97 | 13.08 | 8.94 | 9.48 | 14.01 |
| Total Liabilities | 32.67 | 29.43 | 33.20 | 45.73 | 44.21 | 57.74 | 51.32 | 47.18 | 41.67 | 46.44 | 41.61 | 42.73 | 38.75 |
| Fixed Assets | 15.93 | 15.02 | 13.96 | 17.12 | 19.68 | 26.09 | 25.20 | 25.98 | 24.32 | 23.36 | 21.59 | 22.43 | 21.55 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.09 | 1.58 | 1.88 | 2.81 | 0.33 | 1.09 | 0.99 | 1.56 | 0.08 | 0.11 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Other Assets | 16.69 | 14.36 | 19.19 | 28.47 | 22.90 | 29.72 | 23.26 | 20.82 | 16.21 | 22.04 | 18.41 | 20.17 | 17.04 |
| Total Assets | 32.67 | 29.43 | 33.20 | 45.73 | 44.21 | 57.74 | 51.32 | 47.18 | 41.67 | 46.44 | 41.61 | 42.73 | 38.75 |
Below is a detailed analysis of the balance sheet data for Vadivarhe Speciality Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 12.78 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.78 Cr..
- For Reserves, as of Sep 2025, the value is -19.41 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -15.56 Cr. (Mar 2025) to -19.41 Cr., marking a decline of 3.85 Cr..
- For Borrowings, as of Sep 2025, the value is 31.37 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 36.03 Cr. (Mar 2025) to 31.37 Cr., marking a decrease of 4.66 Cr..
- For Other Liabilities, as of Sep 2025, the value is 14.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.48 Cr. (Mar 2025) to 14.01 Cr., marking an increase of 4.53 Cr..
- For Total Liabilities, as of Sep 2025, the value is 38.75 Cr.. The value appears to be improving (decreasing). It has decreased from 42.73 Cr. (Mar 2025) to 38.75 Cr., marking a decrease of 3.98 Cr..
- For Fixed Assets, as of Sep 2025, the value is 21.55 Cr.. The value appears to be declining and may need further review. It has decreased from 22.43 Cr. (Mar 2025) to 21.55 Cr., marking a decrease of 0.88 Cr..
- For CWIP, as of Sep 2025, the value is 0.11 Cr.. The value appears strong and on an upward trend. It has increased from 0.08 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.03 Cr..
- For Investments, as of Sep 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05 Cr..
- For Other Assets, as of Sep 2025, the value is 17.04 Cr.. The value appears to be declining and may need further review. It has decreased from 20.17 Cr. (Mar 2025) to 17.04 Cr., marking a decrease of 3.13 Cr..
- For Total Assets, as of Sep 2025, the value is 38.75 Cr.. The value appears to be declining and may need further review. It has decreased from 42.73 Cr. (Mar 2025) to 38.75 Cr., marking a decrease of 3.98 Cr..
However, the Borrowings (31.37 Cr.) are higher than the Reserves (-19.41 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.66 | -3.73 | -3.26 | -2.35 | -5.90 | -18.59 | -28.91 | -23.99 | -31.21 | -23.48 | -21.58 | -41.92 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 135.00 | 70.97 | 117.50 | 159.63 | 122.95 | 143.25 | 104.34 | 125.62 | 34.37 | 48.22 | 44.99 | 79.53 |
| Inventory Days | 223.98 | 221.86 | 116.68 | 61.66 | 170.63 | 221.62 | 122.32 | 77.40 | 168.42 | 120.82 | 147.37 | 128.08 |
| Days Payable | 128.58 | 50.10 | 108.01 | 115.85 | 120.38 | 174.61 | 205.42 | 152.95 | 218.56 | 145.63 | 122.81 | 98.83 |
| Cash Conversion Cycle | 230.40 | 242.73 | 126.18 | 105.44 | 173.20 | 190.26 | 21.24 | 50.07 | -15.76 | 23.40 | 69.55 | 108.78 |
| Working Capital Days | -31.58 | 16.30 | 43.06 | 63.14 | 85.54 | 90.35 | -30.65 | 11.45 | -106.86 | -33.09 | 15.39 | -27.83 |
| ROCE % | 4.41% | 25.77% | 22.61% | 29.66% | 7.86% | 2.88% | -25.06% | -5.34% | -24.02% | 7.61% | 10.15% | -22.66% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -7.25 | 0.05 | 1.00 | -8.00 | -2.16 |
| Diluted EPS (Rs.) | -7.25 | 0.05 | 1.00 | -8.00 | -2.16 |
| Cash EPS (Rs.) | -5.80 | 1.41 | 2.30 | -6.12 | -0.74 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -2.17 | 5.08 | 5.03 | 4.13 | 11.65 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -2.17 | 5.08 | 5.03 | 4.13 | 11.65 |
| Revenue From Operations / Share (Rs.) | 29.65 | 31.35 | 34.17 | 16.78 | 20.71 |
| PBDIT / Share (Rs.) | -4.81 | 3.54 | 3.16 | -5.09 | -0.23 |
| PBIT / Share (Rs.) | -6.25 | 2.18 | 1.76 | -6.49 | -1.65 |
| PBT / Share (Rs.) | -7.25 | 1.18 | 0.89 | -7.52 | -2.03 |
| Net Profit / Share (Rs.) | -7.25 | 0.04 | 0.89 | -7.52 | -2.16 |
| PBDIT Margin (%) | -16.21 | 11.29 | 9.23 | -30.30 | -1.13 |
| PBIT Margin (%) | -21.09 | 6.96 | 5.14 | -38.65 | -7.95 |
| PBT Margin (%) | -24.44 | 3.76 | 2.62 | -44.79 | -9.78 |
| Net Profit Margin (%) | -24.44 | 0.15 | 2.62 | -44.79 | -10.42 |
| Return on Networth / Equity (%) | 0.00 | 0.94 | 17.84 | -181.94 | -18.54 |
| Return on Capital Employeed (%) | -38.97 | 10.81 | 9.72 | -37.93 | -7.01 |
| Return On Assets (%) | -21.68 | 0.14 | 2.47 | -23.05 | -5.85 |
| Long Term Debt / Equity (X) | -8.22 | 2.91 | 2.53 | 3.01 | 0.97 |
| Total Debt / Equity (X) | -12.98 | 4.03 | 4.19 | 3.75 | 1.29 |
| Asset Turnover Ratio (%) | 0.89 | 0.91 | 0.99 | 0.48 | 0.53 |
| Current Ratio (X) | 0.89 | 1.14 | 0.86 | 0.72 | 1.11 |
| Quick Ratio (X) | 0.45 | 0.59 | 0.49 | 0.38 | 0.91 |
| Inventory Turnover Ratio (X) | 4.14 | 2.59 | 3.35 | 3.69 | 2.54 |
| Interest Coverage Ratio (X) | -4.63 | 3.52 | 2.74 | -4.14 | -0.24 |
| Interest Coverage Ratio (Post Tax) (X) | -6.02 | 1.05 | 1.53 | -5.27 | -1.84 |
| Enterprise Value (Cr.) | 69.02 | 65.29 | 61.35 | 50.97 | 34.38 |
| EV / Net Operating Revenue (X) | 1.82 | 1.63 | 1.40 | 2.38 | 1.30 |
| EV / EBITDA (X) | -11.23 | 14.42 | 15.20 | -7.84 | -114.95 |
| MarketCap / Net Operating Revenue (X) | 0.88 | 0.98 | 0.80 | 1.49 | 0.60 |
| Price / BV (X) | -12.09 | 6.11 | 5.48 | 6.05 | 1.08 |
| Price / Net Operating Revenue (X) | 0.88 | 0.98 | 0.80 | 1.49 | 0.60 |
| EarningsYield | -0.27 | 0.00 | 0.03 | -0.30 | -0.17 |
After reviewing the key financial ratios for Vadivarhe Speciality Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to -7.25, marking a decrease of 7.30.
- For Diluted EPS (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to -7.25, marking a decrease of 7.30.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.80. This value is below the healthy minimum of 3. It has decreased from 1.41 (Mar 24) to -5.80, marking a decrease of 7.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.17. It has decreased from 5.08 (Mar 24) to -2.17, marking a decrease of 7.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -2.17. It has decreased from 5.08 (Mar 24) to -2.17, marking a decrease of 7.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 29.65. It has decreased from 31.35 (Mar 24) to 29.65, marking a decrease of 1.70.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -4.81. This value is below the healthy minimum of 2. It has decreased from 3.54 (Mar 24) to -4.81, marking a decrease of 8.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.25. This value is below the healthy minimum of 0. It has decreased from 2.18 (Mar 24) to -6.25, marking a decrease of 8.43.
- For PBT / Share (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 0. It has decreased from 1.18 (Mar 24) to -7.25, marking a decrease of 8.43.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -7.25. This value is below the healthy minimum of 2. It has decreased from 0.04 (Mar 24) to -7.25, marking a decrease of 7.29.
- For PBDIT Margin (%), as of Mar 25, the value is -16.21. This value is below the healthy minimum of 10. It has decreased from 11.29 (Mar 24) to -16.21, marking a decrease of 27.50.
- For PBIT Margin (%), as of Mar 25, the value is -21.09. This value is below the healthy minimum of 10. It has decreased from 6.96 (Mar 24) to -21.09, marking a decrease of 28.05.
- For PBT Margin (%), as of Mar 25, the value is -24.44. This value is below the healthy minimum of 10. It has decreased from 3.76 (Mar 24) to -24.44, marking a decrease of 28.20.
- For Net Profit Margin (%), as of Mar 25, the value is -24.44. This value is below the healthy minimum of 5. It has decreased from 0.15 (Mar 24) to -24.44, marking a decrease of 24.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has decreased from 0.94 (Mar 24) to 0.00, marking a decrease of 0.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is -38.97. This value is below the healthy minimum of 10. It has decreased from 10.81 (Mar 24) to -38.97, marking a decrease of 49.78.
- For Return On Assets (%), as of Mar 25, the value is -21.68. This value is below the healthy minimum of 5. It has decreased from 0.14 (Mar 24) to -21.68, marking a decrease of 21.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -8.22. This value is below the healthy minimum of 0.2. It has decreased from 2.91 (Mar 24) to -8.22, marking a decrease of 11.13.
- For Total Debt / Equity (X), as of Mar 25, the value is -12.98. This value is within the healthy range. It has decreased from 4.03 (Mar 24) to -12.98, marking a decrease of 17.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has decreased from 0.91 (Mar 24) to 0.89, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1.5. It has decreased from 1.14 (Mar 24) to 0.89, marking a decrease of 0.25.
- For Quick Ratio (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.45, marking a decrease of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.14. This value is within the healthy range. It has increased from 2.59 (Mar 24) to 4.14, marking an increase of 1.55.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -4.63. This value is below the healthy minimum of 3. It has decreased from 3.52 (Mar 24) to -4.63, marking a decrease of 8.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -6.02. This value is below the healthy minimum of 3. It has decreased from 1.05 (Mar 24) to -6.02, marking a decrease of 7.07.
- For Enterprise Value (Cr.), as of Mar 25, the value is 69.02. It has increased from 65.29 (Mar 24) to 69.02, marking an increase of 3.73.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.82. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.82, marking an increase of 0.19.
- For EV / EBITDA (X), as of Mar 25, the value is -11.23. This value is below the healthy minimum of 5. It has decreased from 14.42 (Mar 24) to -11.23, marking a decrease of 25.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.88, marking a decrease of 0.10.
- For Price / BV (X), as of Mar 25, the value is -12.09. This value is below the healthy minimum of 1. It has decreased from 6.11 (Mar 24) to -12.09, marking a decrease of 18.20.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.88, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is -0.27. This value is below the healthy minimum of 5. It has decreased from 0.00 (Mar 24) to -0.27, marking a decrease of 0.27.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vadivarhe Speciality Chemicals Ltd:
- Net Profit Margin: -24.44%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -38.97% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -6.02
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.45
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 58.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -12.98
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -24.44%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Gat No. 204, Nashik-Mumbai Highway, Nasik Maharashtra 422403 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sunil Haripant Pophale | Chairman & Executive Director |
| Mrs. Meena Sunil Pophale | Whole Time Director |
| Mr. Prasanna Prabhakar Rege | Independent Director |
| Mr. Ravindra Keshav Paranjpe | Independent Director |
| Mrs. Uttara Adwait Kher | Independent Director |
FAQ
What is the intrinsic value of Vadivarhe Speciality Chemicals Ltd?
Vadivarhe Speciality Chemicals Ltd's intrinsic value (as of 21 January 2026) is ₹305.78 which is 1265.09% higher the current market price of ₹22.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹28.6 Cr. market cap, FY2025-2026 high/low of ₹41.7/16.0, reserves of ₹-19.41 Cr, and liabilities of ₹38.75 Cr.
What is the Market Cap of Vadivarhe Speciality Chemicals Ltd?
The Market Cap of Vadivarhe Speciality Chemicals Ltd is 28.6 Cr..
What is the current Stock Price of Vadivarhe Speciality Chemicals Ltd as on 21 January 2026?
The current stock price of Vadivarhe Speciality Chemicals Ltd as on 21 January 2026 is ₹22.4.
What is the High / Low of Vadivarhe Speciality Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vadivarhe Speciality Chemicals Ltd stocks is ₹41.7/16.0.
What is the Stock P/E of Vadivarhe Speciality Chemicals Ltd?
The Stock P/E of Vadivarhe Speciality Chemicals Ltd is .
What is the Book Value of Vadivarhe Speciality Chemicals Ltd?
The Book Value of Vadivarhe Speciality Chemicals Ltd is 5.19.
What is the Dividend Yield of Vadivarhe Speciality Chemicals Ltd?
The Dividend Yield of Vadivarhe Speciality Chemicals Ltd is 0.00 %.
What is the ROCE of Vadivarhe Speciality Chemicals Ltd?
The ROCE of Vadivarhe Speciality Chemicals Ltd is 22.7 %.
What is the ROE of Vadivarhe Speciality Chemicals Ltd?
The ROE of Vadivarhe Speciality Chemicals Ltd is 495 %.
What is the Face Value of Vadivarhe Speciality Chemicals Ltd?
The Face Value of Vadivarhe Speciality Chemicals Ltd is 10.0.